Please login to the form below

Not currently logged in
Email:
Password:

Advaxis

This page shows the latest Advaxis news and features for those working in and with pharma, biotech and healthcare.

Amgen enters into $540m immunotherapy collaboration

Amgen enters into $540m immunotherapy collaboration

Amgen enters into $540m immunotherapy collaboration. Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO. ... Amgen has bought into a preclinical cancer immunotherapy treatment developed by small US biotech Advaxis, in a deal

Latest news

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Acquisition - company. 705. Advaxis/ SELLAS Life Sciences Group. Advaxis' Lm-based antigen delivery technology with SELLAS’WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S) (pre-clinical).

  • Deal Watch August 2016 Deal Watch August 2016

    624. Advaxis (US). Amgen (US). Licence. ADXS-NEO, preclinical investigational cancer immunotherapy treatment.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics